Designer drugs

European Commission proposes to control two harmful new psychoactive substances

Retrieved on: 
Saturday, March 13, 2021
Psychoactive drugs, Designer drugs, Cannabinoids, 4F-MDMB-BINACA, MDMB-4en-PINACA, Synthetic cannabinoids, 5F-EMB-PINACA, MDMB-FUBICA

Today, the European Commission has proposed to control two harmful new psychoactive substances (NPS) across the European Union.

Key Points: 
  • Today, the European Commission has proposed to control two harmful new psychoactive substances (NPS) across the European Union.
  • The substances in question MDMB-4en-PINACA and 4F-MDMB-BICA are both synthetic cannabinoids, which have been raising health concerns in Europe (1).
  • The proposal to control the substances is based on risk assessments conducted by the EU drugs agency (EMCDDA) in December 2020.
  • The substances have been detected in smoking mixtures, powders, liquids (including e-liquids) and paper impregnated with the substance (including blotters).

Nalu Bio Partners with World-Class Scientists to Evaluate Synthetic CBD for Non-Opioid Pain Management

Retrieved on: 
Thursday, March 4, 2021
Psychoactive drugs, Designer drugs, Drug culture, Synthetic cannabinoids, Pain management, Opioid, Cannabinoid, Addiction

The collaboration with Prof. Mackie aims to demonstrate that synthetic CBD has the same potency and efficacy as plant-derived CBD.

Key Points: 
  • The collaboration with Prof. Mackie aims to demonstrate that synthetic CBD has the same potency and efficacy as plant-derived CBD.
  • We are very excited to be working with these distinguished scientists to help us realize the full therapeutic potential of synthetic cannabinoids.
  • We are especially pleased to welcome Ken to our Advisory Board," said Caitlyn Krebs, Co-Founder & CEO of Nalu Bio.
  • Nalu Bio is creating a new category of cannabinoids and wellness ingredients which will offer great therapeutic promise for the treatment of pain management and opioid addiction.

Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program

Retrieved on: 
Friday, February 19, 2021
Psychoactive drugs, Entheogens, Amines, Hallucinations, Mycotoxins, Designer drugs, Psychedelic drug, N,N-Dimethyltryptamine, Psilocin, Hallucinogen, O-Acetylpsilocin, Diethyltryptamine

Dalton is a class 4 controlled substance licensed manufacturer with Health Canada and has extensive experience in synthesizingpsilocybinand tryptamine derivatives.

Key Points: 
  • Dalton is a class 4 controlled substance licensed manufacturer with Health Canada and has extensive experience in synthesizingpsilocybinand tryptamine derivatives.
  • We are very pleased to have appointed DaltonPharma Services to synthesize our GMP DMT supply, said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.
  • N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics likeLSD, ketamine, psilocybin and psilocin.
  • Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

EMCDDA technical report on the new psychoactive substance methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate (4F-MDMB-BICA)

Retrieved on: 
Tuesday, December 22, 2020
Cannabinoids, Designer drugs, Chemistry, Organic compounds, Organic chemistry, 4F-MDMB-BINACA, MDMB-FUBINACA, MDMB-FUBICA

The purpose of this technical report is to provide an analysis of the available information on methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate (commonly known as 4F-MDMB-BICA), a synthetic receptor cannabinoid agonist that has recently emerged on the drug market in Europe, in order to support the risk assessment of the substance which has been requested by the European Commission in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended).

Key Points: 
  • The purpose of this technical report is to provide an analysis of the available information on methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate (commonly known as 4F-MDMB-BICA), a synthetic receptor cannabinoid agonist that has recently emerged on the drug market in Europe, in order to support the risk assessment of the substance which has been requested by the European Commission in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended).
  • Explanatory note: In the interests of public health protection the EMCDDA is releasing this report before formal copy editing and page layout in the EMCDDA house style.
  • The final report will be available in due course.

EMCDDA technical report on the new psychoactive substance methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]amino}butanoate (MDMB-4en-PINACA)

Retrieved on: 
Tuesday, December 22, 2020
Psychoactive drugs, Designer drugs, Cannabinoids, MDMB-4en-PINACA, Synthetic cannabinoids, MDMB-FUBINACA, MDMB-FUBICA

The purpose of this technical report is to provide an analysis of the available information on methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]amino}butanoate (commonly known as MDMB-4en-PINACA), a synthetic cannabinoid receptor agonist that has recently emerged on the drug market in Europe, in order to support the risk assessment of the substance which has been requested by the European Commission in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended).

Key Points: 
  • The purpose of this technical report is to provide an analysis of the available information on methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]amino}butanoate (commonly known as MDMB-4en-PINACA), a synthetic cannabinoid receptor agonist that has recently emerged on the drug market in Europe, in order to support the risk assessment of the substance which has been requested by the European Commission in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended).
  • Explanatory note: In the interests of public health protection the EMCDDA is releasing this report before formal copy editing and page layout in the EMCDDA house style.
  • The final report will be available in due course.

Reitox national focal points’ activities during the COVID-19 pandemic

Retrieved on: 
Saturday, December 12, 2020
European Monitoring Centre for Drugs and Drug Addiction, European Union, Addiction, Designer drugs, Mind, Psychology, Branches of biology

This report highlights the responses taken by the EMCDDA's Reitox network of national focal points to the COVID-19 crisis and describes the challenges met by the organisations and the strategies produced to overcome these challenges.

Key Points: 
  • This report highlights the responses taken by the EMCDDA's Reitox network of national focal points to the COVID-19 crisis and describes the challenges met by the organisations and the strategies produced to overcome these challenges.
  • The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe.
  • Inaugurated in Lisbon in 1995, it is one of the EUs decentralised agencies.
  • Read more >>

Usona Institute Publishes Synthesis and Characterization of cGMP 5-MeO-DMT

Retrieved on: 
Tuesday, December 8, 2020
Alternative medicine, Mental health, Health, Research, Science, Pharmaceutical, Biotechnology, Psychoactive drugs, Entheogens, Ayahuasca, Designer drugs, Psychedelic drugs, 5-MeO-DMT, N,N-Dimethyltryptamine, Psilocybin

Usona Institute has published a multigram-scale process describing the synthesis of 5-MeO-DMT in the open-access journal ACS Omega .

Key Points: 
  • Usona Institute has published a multigram-scale process describing the synthesis of 5-MeO-DMT in the open-access journal ACS Omega .
  • The motivation to advance 5-MeO-DMT clinically is built upon several decades of investigation describing pioneering human exploration with this substance.
  • Alex Sherwood, PhD, Usona medicinal chemist
    5-MeO-DMT is a potent, short-acting, and naturally occurring psychedelic.
  • Usona Institute is a 501(c)(3) nonprofit medical research organization (MRO) that conducts and supports pre-clinical and clinical research to further the understanding of the therapeutic effects of psilocybin and other consciousness-expanding medicines.

Report on the risk assessment of N,N-diethyl-2- [[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1Hbenzimidazole- 1-ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)

Retrieved on: 
Friday, November 13, 2020
Benzimidazoles, Designer drugs, Analgesics, Opioids, Isotonitazene, Framework decision, Regulation (EU) No. 305/2011, Drugs, Health care

This publication presents the data and findings of the risk assessment on N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1- ethanamine (isotonitazene), carried out by the extended Scientific Committee of the EMCDDA on 26 May 2020.

Key Points: 
  • This publication presents the data and findings of the risk assessment on N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1- ethanamine (isotonitazene), carried out by the extended Scientific Committee of the EMCDDA on 26 May 2020.
  • On the basis of the Risk Assessment Report, on 2 September 2020, the Commission decided that isotonitazene should be included in the definition of 'drug', in the Annex to Framework Decision 2004/757/JHA.
  • Member States shall bring into force the laws, regulations and administrative provisions necessary to comply with Commission Delegated Directive (EU) 2020/1687 by 3 June 2021.

CBDProducts.com Releases New Pain Relief CBD Cream That Offers Up To 90% Absorption

Retrieved on: 
Wednesday, November 11, 2020
Euphoriants, Cannabinoid, Hash oil, Chemistry, Antiemetics, Designer drugs

Made with NanoZorb Technology in an FDA registered facility, this CBD cream from Cannabinoid Balance offers fast-acting, soothing relief.

Key Points: 
  • Made with NanoZorb Technology in an FDA registered facility, this CBD cream from Cannabinoid Balance offers fast-acting, soothing relief.
  • In fact, this nanotechnology will start to deliver all the goodness of Cannabinoid Balance Pain Relief Cream+ within just 2 minutes of application thanks to NanoZorb boosting absorption into the bloodstream to 90% vs 18% with other non-nano products.
  • *
    Like all Cannabinoid Balance products, Cannabinoid Balance Pain Relief Cream+ is:
    Cannabinoid Balance products are all-natural and free of synthetics, sugar, binders, fillers, wax, shellac, talcum, and animal gelatin.
  • A line of consumer products that includes Cannabinoid Balance Original+, Cannabinoid Balance Sleep+, Cannabinoid Balance CBD Gummies+, Cannabinoid Balance Pain Relief Cream and Cannabinoid Balance Pet+.

EMCDDA initial report on the new psychoactive substance MDMB-4en-PINACA

Retrieved on: 
Wednesday, November 4, 2020
Psychoactive drugs, Cannabis smoking, Herbalism, Medicinal plants, Designer drugs, Euphoriants, Synthetic cannabinoids, Effects of cannabis, Medical cannabis, Cannabinoid, Cannabis, Medical cannabis research

Similar to other synthetic cannabinoids, it is sold as a legal replacement for cannabis and controlled synthetic cannabinoids.

Key Points: 
  • Similar to other synthetic cannabinoids, it is sold as a legal replacement for cannabis and controlled synthetic cannabinoids.
  • Because of their high potency, synthetic cannabinoids can pose a high risk of severe poisoning, which in some cases can be fatal.
  • Based on potential public health risks, an initial report has been prepared and submitted to the Commission and the Member States, in accordance with Article 5b of Regulation (EC) No 1920/2006 (as amended).
  • Please note: this is an advance copy of the report which has not yet been edited.